Application of kojic acid scaffold in the design of non-tyrosinase enzyme inhibitors
© 2022 John Wiley & Sons A/S..
Kojic acid (KA) is a hydroxypyranone natural metabolite mainly known as tyrosinase inhibitor. Currently, this compound is used as a whitening agent in cosmetics and as an anti-browning agent in food industry. Given the easy-manipulation in different positions of the KA molecule, many investigations have been carried out to find new tyrosinase inhibitors derived from KA. Beside anti-tyrosinase activity, many KA-based compounds have been designed for targeting other enzymes including human neutrophil elastase, catechol-O-methyltransferase, matrix metalloproteinases, monoamine oxidase, human lactate dehydrogenase, endonucleases, D-amino acid oxidase, and receptors such as histamine H3 and apelin (APJ) receptors. This review could help biochemists and medicinal chemists in designing diverse KA-derived enzyme inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Chemical biology & drug design - 100(2022), 2 vom: 01. Aug., Seite 290-303 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ashooriha, Morteza [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.07.2022 Date Revised 02.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cbdd.14065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340809213 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340809213 | ||
| 003 | DE-627 | ||
| 005 | 20231226010317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cbdd.14065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340809213 | ||
| 035 | |a (NLM)35555863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ashooriha, Morteza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of kojic acid scaffold in the design of non-tyrosinase enzyme inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.07.2022 | ||
| 500 | |a Date Revised 02.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons A/S. | ||
| 520 | |a Kojic acid (KA) is a hydroxypyranone natural metabolite mainly known as tyrosinase inhibitor. Currently, this compound is used as a whitening agent in cosmetics and as an anti-browning agent in food industry. Given the easy-manipulation in different positions of the KA molecule, many investigations have been carried out to find new tyrosinase inhibitors derived from KA. Beside anti-tyrosinase activity, many KA-based compounds have been designed for targeting other enzymes including human neutrophil elastase, catechol-O-methyltransferase, matrix metalloproteinases, monoamine oxidase, human lactate dehydrogenase, endonucleases, D-amino acid oxidase, and receptors such as histamine H3 and apelin (APJ) receptors. This review could help biochemists and medicinal chemists in designing diverse KA-derived enzyme inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 4H-pyran-4-one | |
| 650 | 4 | |a design of inhibitors | |
| 650 | 4 | |a enzyme inhibitors | |
| 650 | 4 | |a kojic acid | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrones |2 NLM | |
| 650 | 7 | |a kojic acid |2 NLM | |
| 650 | 7 | |a 6K23F1TT52 |2 NLM | |
| 650 | 7 | |a Monophenol Monooxygenase |2 NLM | |
| 650 | 7 | |a EC 1.14.18.1 |2 NLM | |
| 650 | 7 | |a Catechol O-Methyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.1.1.6 |2 NLM | |
| 700 | 1 | |a Ahmadi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Ahadi, Hamideh |e verfasserin |4 aut | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical biology & drug design |d 2006 |g 100(2022), 2 vom: 01. Aug., Seite 290-303 |w (DE-627)NLM160848377 |x 1747-0285 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2022 |g number:2 |g day:01 |g month:08 |g pages:290-303 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cbdd.14065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2022 |e 2 |b 01 |c 08 |h 290-303 | ||